Accelerate to discover

Back to filter

Related topics

Real-time and quantitative analysis of Macrophage Phagocytosis with RTCA eSight

Agilent technologies

Feb 23, 2024

The eSight is currently the only instrument that interrogates cell health and behavior using cellular
impedance
...

Visualization of Tumor-Related Blood Vessels in Small Animals by Photoacoustic 3D Imaging System

Luxonus

Feb 21, 2024

In Vivo Label-Free Observation of Tumor-Related Blood Vessels in Small Animals Using a Newly Designed Photoacoustic 3D...

Therapeutic effects of mesenchymal stem cells in myocardial infarction

S-Sharp

Feb 19, 2024

Intrapericardial hydrogel injection generates high cell retention and augments therapeutic effects of mesenchymal stem...

Whole-slide biomarker quantitation in 82-patient NSCLC cohort study of acquired resistance to PD-(L)

RareCyte

Feb 7, 2024

Samples from 82 patients with NSCLC and matched pre- and post-ICI biopsies were subjected to genomic profiling and to...

Mar 2, 2024

Evaluation with BLI of synthetic immune checkpoint engagers in allogenic mice

Spectral Instruments Imaging

Jan 17, 2024

Synthetic immune checkpoint engagers protect HLA-deficient iPSCs and derivatives from innate immune cell cytotoxicity

Application of focal X-ray irradiation in canaries

Precision X-Ray

Jan 15, 2024

Effects of the depletion of neural progenitors by focal X-ray irradiation on song production and perception in canaries

Radiation planning for image guided preclinical radiotherapy

Precision X-Ray

Jan 12, 2024

Doctoral Thesis, Stefan van Hoof, Maastricht University 2019

Mar 2, 2024

IVM and single cell transcriptomic analysis for engraftment of mesenchymal stem cells

IVIM Technology

Jan 10, 2024

To facilitate the translation of preclinical studies into clinical practice, the precise in vivo behaviors of the...

Show all topics (10)

Digital measurement for HER2 amplifcation in HER2 equivocal breast cancer diagnosis

Sep 20, 2017

Currently, there are no recommended alternative assays for HER2 cases deemed equivocal by immunohistochemistry and fuorescent in situ hybridization. Digital PCR (ddPCR), a highly accurate method to determine DNA copy number, could be a robust alternative for clinical HER2 diagnostics. HER2 and CEP17 copy numbers were quantifed using two ddPCR platforms (QX200 and RainDrop) in 102 samples of invasive breast cancers. Compared to routine assays, ddPCR gave a sensitivity
and specifcity of 82.8% and 97.3% respectively, with a kappa value of 0.833 (p<0.001). Moreover, the method proved to be robust as the results from two platforms was highly correlated R2=0.91; Concordance rate=97%; κ=0.923, P<0.001). Its performance was further tested on 114 HER2 equivocal cases in an independent validation cohort. 75% (21/28) of cases with HER2 amplifcation and 95% (82/86) of HER2 non-amplifed case were classifed as positive and negative by ddPCR respectively (κ=0.709, P<0.001). Notably, in the HER2 amplifed cases, a lower percentage of HER2 positive cells could be related to the discordant results. Altogether, ddPCR is a robust alternative for clinical HER2 diagnostics. However, intratumoral heterogeneity of HER2 status still pose a challenge for HER2 analysis by ddPCR.

Read more

Scientific paper
Application

Get more info

Regina Fillerová

Field application specialist

Regina

Fillerová

+420 731 127 718

Send Message

Brand profile

RainDance Technologies

RainDance company’s ultra-sensitive genomic tools enable research of novel non-invasive liquid biopsy applications that should result in more accurate, reliable, cost-effective, and early detection of cancer and other inherited and infectious diseases.

Related products

Capable of generating more than a billion reactions in a single day, the RainDrop system surpasses all existing technologies and establishes a new performance standard in sensitivity, quantitation and multiplexing.

show detail

A fast, accurate and low-cost NGS target enrichment system that features award-winning instrumentation and pre-validated gene panels, as well as flexible open source options.

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey